CAMP4 Therapeutics Corporation (CAMP)
US — Healthcare Sector
Automate Your Wheel Strategy on CAMP
With Tiblio's Option Bot, you can configure your own wheel strategy including CAMP - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CAMP
- Rev/Share 0.0774
- Book/Share 2.644
- PB 0.5938
- Debt/Equity 0.1526
- CurrentRatio 8.0228
- ROIC -0.8436
- MktCap 31652886.0
- FreeCF/Share -2.5332
- PFCF -0.6406
- PE -0.5915
- Debt/Assets 0.1254
- DivYield 0
- ROE 7.0857
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
---|---|---|---|---|---|---|---|
Initiation | CAMP | Wedbush | -- | Outperform | -- | $8 | May 27, 2025 |
News
CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting
CAMP
Published: May 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
Published: May 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
Haploinsufficient SYNGAP1 mice treated with CMP-SYNGAP-01 demonstrated an increase in SYNGAP1 protein levels; treatment rescued multiple SYNGAP1-dependent behavioral phenotypes
Read More
CalAmp Synovia to Showcase Leading Student Transportation Solutions at STN East 2025
CAMP
Published: March 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
Published: March 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
Leading Fleet Management Innovator to Engage with Industry Experts at Booth 108 Leading Fleet Management Innovator to Engage with Industry Experts at Booth 108
Read More
About CAMP4 Therapeutics Corporation (CAMP)
- IPO Date 2024-10-11
- Website https://www.camp4tx.com/
- Industry Biotechnology
- CEO Mr. Joshua Mandel-Brehm
- Employees 55
CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.